A comparative analysis of adiponectin and soluble CD36 levels between diabetic and non-diabetic metabolic syndrome patients
DOI:
https://doi.org/10.18203/2320-6012.ijrms20244090Keywords:
Adiponectin, Diabetes mellitus, Metabolic syndrome, Soluble CD36Abstract
Background: Metabolic syndrome refers to a constellation of interrelated metabolic risk factors that promote the development of type-2 diabetes mellitus (T2 DM) and cardiovascular diseases (CVD). The purpose of this study was to compare the serum levels of adiponectin and soluble CD36 between diabetic and non-diabetic metabolic syndrome patients. The aim of this study was to compare the serum levels of adiponectin and soluble CD36 between diabetic and non-diabetic metabolic syndrome patients.
Methods: This cross-sectional analytical study, conducted at the Outpatient Department and Department of Immunology at BIRDEM General Hospital over 12 months, included 80 participants: 60 with metabolic syndrome (30 type-2 diabetic and 30 non-diabetic) and 20 healthy controls. Participants underwent clinical examinations, anthropometric measurements and blood tests for serum analysis of adiponectin and soluble CD36 using ELISA and immunonephelometry. Data were analyzed using nonparametric tests (Mann-Whitney U test, Levene's test) and correlation analyses (Pearson and Spearman) with p<0.05, using SPSS version 20.
Results: Metabolic syndrome patients had higher weight, BMI, waist circumference and blood pressure compared to healthy subjects. Adiponectin and soluble CD36 levels were significantly lower in metabolic syndrome patients, with differences between diabetic and non-diabetic groups. Adiponectin negatively correlated with waist circumference, blood pressure and triglycerides, while soluble CD36 positively correlated with waist circumference, diastolic blood pressure and triglycerides.
Conclusions: In conclusion, our study highlights that adiponectin and soluble CD36 levels are significantly altered in diabetic versus non-diabetic metabolic syndrome patients, suggesting their potential as biomarkers for metabolic syndrome.
Metrics
References
Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, et al. Harmonizing the metabolic syndrome: a joint interim statement of the international diabetes federation task force on epidemiology and prevention; national heart, lung and blood institute; American heart association; world heart federation; international atherosclerosis society; and international association for the study of obesity. Circulation. 2009;120(16):1640-5.
Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. The lancet. 2005;16;365(9468):1415-28.
Sattar N, McConnachie A, Shaper AG, Blauw GJ, Buckley BM, de Craen AJ, et al. Can metabolic syndrome usefully predict cardiovascular disease and diabetes? Outcome data from two prospective studies. The Lancet. 2008;7;371(9628):1927-35.
Meigs JB, Rutter MK, Sullivan LM, Fox CS, D'Agostino Sr RB, Wilson PW. Impact of insulin resistance on risk of type 2 diabetes and cardiovascular disease in people with metabolic syndrome. Diabetes care. 2007;1;30(5):1219-25.
Hossain MS, Rahaman MZ, Banik S, Sarwar MS, Yokota K. Prevalence of the metabolic syndrome in diabetic patients living in a coastal region of Bangladesh. Int J Pharma Sci Res. 2012;1;3(8):2633.
Hanley AJ, Festa A, D’Agostino Jr RB, Wagenknecht LE, Savage PJ, Tracy RP, et al. Metabolic and inflammation variable clusters and prediction of type 2 diabetes: factor analysis using directly measured insulin sensitivity. Diabetes. 2004;1;53(7):1773-81.
Hotamisligil GS. Inflammation and metabolic disorders. Nature. 2006;14;444(7121):860-7.
Ryo M, Nakamura T, Kihara S, Kumada M, Shibazaki S, Takahashi M, et al. Adiponectin as a biomarker of the metabolic syndrome. Circulation journal. 2004;68(11):975-81.
Handberg A, Højlund K, Gastaldelli A, Flyvbjerg A, Dekker JM, Petrie J, et al. investigators. Plasma sCD36 is associated with markers of atherosclerosis, insulin resistance and fatty liver in a nondiabetic healthy population. Journal of internal medicine. 2012;271(3):294-304.
Matsuzawa Y, Funahashi T, Kihara S, Shimomura I. Adiponectin and metabolic syndrome. Arteriosclerosis, Thrombosis and Vas Biol. 2004;1;24(1):29-33.
Koonen DP, Jacobs RL, Febbraio M, Young ME, Soltys CL, Ong H, et al. Increased hepatic CD36 expression contributes to dyslipidemia associated with diet-induced obesity. Diabetes. 2007;1;56(12):2863-71.
Handberg A, Levin K, Højlund K, Beck-Nielsen H. Identification of the oxidized low-density lipoprotein scavenger receptor CD36 in plasma: a novel marker of insulin resistance. Circulation. 2006;12;114(11):1169-76.
Grundy SM. Metabolic syndrome: connecting and reconciling cardiovascular and diabetes worlds. J Am Coll Cardiol. 2006;21;47(6):1093-100.
Alberti G, Zimmet P, Shaw J, Grundy SM. The IDF consensus worldwide definition of the metabolic syndrome. Brussels: Int Diab Feder. 2006;23(5):469-80.
Nestel P, Lyu R, Low LP, Sheu WH, Nitiyanant W, Saito I, et al. Metabolic syndrome: recent prevalence in East and Southeast Asian populations. Asia Pacific J Clin Nutr. 2007;1;16(2):1.
Billah SM, Jahan MS, Jesmine S, Keobouahome B, Watanabe Y, Kinoue T. Metabolic Syndrome in Bangladesh using NCEP adult treatment panel III Criteria. Jpn J ClinEcol. 2011;20(1):61-70.
Stojanović S, Deljanin-Ilić M, Ilić S, Petrović D, Đukić S. The significance of adiponectin as a biomarker in metabolic syndrome and/or coronary artery disease. Vojnosanitetski pregled. 2015;72(9):779-84.
Downloads
Published
How to Cite
Issue
Section
